Attana Immunity Profiles for Mpox and an efficient use of limited resources
During the weekend we have received several questions about Attana’s Immunity Profiles and their potential applications for the increased number of people infected by Mpox.
Attana’s Immunity profiles is generic in that sense that the only necessary change between immunity profiles for different pathogens is the pathogen specific antigen on the sensor surface, in this case the Mpox virus. Hence, it would be fast process to have a Immunity Profile assays for Mpox up and running.
The Mpox immunity profile could be applied to determine the protection against the Mpox for individuals and groups. Given that it seems that vaccine is currently a limiting resource to stop the spreading, the benefit of immunity profiling would be optimal distribution of vaccine in the hot zones to minimize spreading by allocating the vaccine to the persons who needs it and not spend it on already protected individuals.
In Sweden, and other European countries, the near time application would be to check previously vaccinated people and recommend extra doses. According to what we have heard, people in Sweden over 50 years have been vaccinated in their youth. However, it is unclear how many vaccine doses that would be necessary to re-activate the protection.
Attana has a tool, the immunity profile, to determine the protection and help to prioritize who should have vaccination. However, it needs to be an organization that has the resources and all other necessary competence to implement the use of the Immunity Profiles.
The picture depicts immunity profiles of a non-exposed or non-vaccinated person, an exposed or vaccinated person with limited protection and an exposes or vaccinated person with good protection.
For more information, please contact:
Teodor Aastrup, CEO
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
